Acne vulgaris is one of the most common skin diseases. The disease takes a severe course in 5% of cases. In these cases, treatment is provided with systemic isotretinoin. The Lidose technology used in Aknekutan* medication reduces the course dose of isotretinoin without a decrease in the therapeutic efficacy. Material and methods. 30 patients with moderately severe to severe acne were involved. The patients took the drug at a daily dose of 0.4—0.8 mg per kg of body weight, with the cumulative course dose being 100—120 mg/kg. The second study was devoted to analyzing the efficacy of the proposed therapeutic regimen with low doses of Aknekutan in combination with immunomodulator viferon in patients with moderate to moderately severe acne. Results. The study confirms the high clinical efficacy of Aknekutan. Clinical recovery was observed in all patients. Conclusions. The findings indicate that standard (100—120 mg/kg) dose of Aknekutan is effective for treating severe and moderately severe forms of acne, while reduced doses of Aknekutan (40—60 mg/kg) in combination with the immunomodulator viferon can possibly be used to treat moderately severe and moderate forms of acne.